PhD defence

The Quantitative Clinical Pharmacology group is led by Prof. Dr. Catherijne Knibbe. Her research group aims to define how to adjust a drug dose in special patient populations such as (prematurely born) neonates or children, obese individuals or critically ill patients. Through combining the statistical…

Prof.Dr. Herman van Vlijmen was appointed as Professor of Computational Drug Discovery at the Division of Medicinal Chemistry in Leiden on April 15th, 2008. He will give his Inaugural Lecture on May 18th, 2009.

One of the main challenges in the development of an effective anti-cancer vaccine is the generation of an adequate and directed cellular immune response.

The majority (80%) of e-waste generated globally are recycled informally in developing countries.

PhD defence

At the Leiden Curious Minds Centre, our research focuses on the relationship of exploratory behaviour and discovery learning to curiosity and the way children regulate their behaviour and emotions. We want to improve our understanding of how children can and do become more and more the captain of their…

Lecture

LUMC researchers are looking for factors that point to illness at an early stage.

Health workers have always sought ways to fight disease in vulnerable groups in the population. It is now clear that such research also benefits more prosperous countries. African worm infections and innovative thermometers have shown Leiden researchers how to fight diseases of affluence and keep health…

Leiden Institute of Advanced Computer Science (LIACS)

LUMC researchers are looking for factors that point to illness at an early stage.

Many metalloenzymes that are key to bioenergetics are membrane enzymes, with canonical examples the complexes I, II, III and IV in the mitochondrial inner membrane. To study these enzymes in a native-like lipid membrane environment, we aim to develop novel bioelectrochemical techniques.

The Institute of Biology Leiden (IBL) is an internationally oriented institute for research and education in biology. We are part of the Faculty of Science at Leiden University.

Parasitic worms and stomach bacteria suppress immune reactions such as allergic responses. Parasitologist Hermelijn Smits and lung specialist Christian Taube from the LUMC are trying to learn from these micro-organisms.

Knowledge institutions in the Netherlands are to work together with the pharma and biotech industries to accelerate drug discovery and development. To bridge the ‘lab-to-life’ gap, Leiden University and the LUMC have, as coordinators of Academic Pharma, submitted an application to the National Growth…

Multiple Sclerosis, Parkinson’s and Alzheimer’s disease are the most common neurodegenerative disorders. Unfortunately, no effective treatments are currently available to halt the progression of these neuroinflammatory diseases [1].

Streptomyces present a valuable platform for natural product discovery. Lugdunomycin is a novel angucycline-derived polyketide from Streptomyces sp QL37, with unprecedented skeleton and antimicrobial activity.

Tuberculosis causes 1.5 million deaths yearly and anti-tuberculosis therapies are threatened by emergence of drug resistance. Development of innovative drug combinations should be accelerated with the use of translational pharmacological models. Moreover, host-directed therapies (HDT), which stimulate…

Division contact information & address

Matthias Barz has been appointed full Professor of Biotherapeutics Delivery at the Leiden Academic Centre for Drug Research (LACDR).

The Faculty of Science is located at the Leiden Bio Science Park. It was founded more than two centuries ago and currently, more than 8000 people are working and studying at the eight institutes.

Allosteric modulation has long been recognized as a general and widespread mechanism for the control of protein function. Modulators bind to regulatory sites distinct from the active site on the protein, resulting in conformational changes that may profoundly influence protein function. This concept…

Promotor: Prof.dr. A.P. IJzerman, Co-Promotor: L.H. Heitman

Particles are omnipresent in biopharmaceutical products. In protein-based therapeutics such particles are generally associated with impurities, either derived from the drug product itself (e.g. protein aggregates), or from extrinsic contaminations (e.g. cellulose fibers).

Edith Schippers, Minister of Health, will be investing six million euros over the coming four years to boost research on new antibiotics. The programme will be set up by several different parties, including the Leiden Centre for Antimicrobial Research.

As a student of Bio-Pharmaceutical Sciences, you have a strong interest in drug development: from the onset of diseases to the effects of individual drugs in the body. Is that true for you? Then, Bio-Pharmaceutical Sciences might be the right study programme for you!

Psychology teacher of the year is Evelien Broekhof. The Master Thesis Awards are for Yanna Naeije and Arian Memarpouri. Mirjam Wever wins the PhD Paper Prize; Jip Aarts wins the PhD Wild Card: Academic Citizenship. Congratulations!

PhD defence

PhD defence

PhD defence

PhD defence

The Collective Experience of Empathic Data Systems (CEEDs) consortium developed novel integrated technologies that support experiencing, analysing and understanding of very large datasets.

Can we build a biosensor to detect neuroblastoma markers in urine using the chemotaxis system in E. coli?

Integrins play an essential role in multicellular life by connecting cells to the extracellular matrix.

How can Staphylococcus aureus bacteria subvert the host immune system?

Researchers from the Institute of Biology Leiden have discovered how good intestinal bacteria regulate our innate immune system. This surprising discovery could make it possible to treat diseases related to inflammation, such as diabetes and colitis, with a cocktail of good bacteria. Publication in…

This thesis discusses the discovery potential of Intensity Frontier experiments.

The Saalian archaeological record at Maastricht-Belvédère (the Netherlands).

Does medicine make patients feel better or worse? We are getting better at predicting this from people’s DNA profiles, says Professor Jesse Swen. ‘It never fails to fascinate me how one DNA base pair can have such a huge effect on treatment with medication and the outcome.’

Peter Flach is Professor of Artificial Intelligence at the University of Bristol. An internationally leading scholar in the evaluation and improvement of machine learning models using ROC analysis and calibration, he has also published on mining highly structured data, on knowledge-driven and explainable…

The ongoing increase in antimicrobial resistance combined with the low discovery of novel antibiotics is a serious threat to our health care.

Antimicrobial drugs constitute a fundamental part of modern medicine. The global rise in antimicrobial resistance poses a major threat to global health.

This dissertation contains four works during my PhD. Different biomaterials have been designed based on coiled-coil peptides. These biomaterials have a range of applications, inclusing drug delivery, cell sorting to cell-cell fusion.

The drug BIA 10-2474 inhibits fatty acid amide hydrolase (FAAH), a lipase that degrades a specific endocannabinoid. On the basis of this activity, BIA 10-2474 was being developed as a potential treatment for anxiety and pain. In a phase 1 trial of the drug, one subject died, and four others suffered…

Aim of the proposal is to develop lugdunomycin into a drug candidate able to treat infectious diseases caused by multi-drug resistant pathogens.

To increase clinical success rate of drugs, a better understanding of drug action mechanism and disease dynamics is required. Metabolomics, which studies small molecules involved in biochemical processes in organisms, has shown to be a useful tool for this better understanding.

Fungal infections pose a significant threat to individuals with compromised immune systems and despite advancements in diagnosis and treatment, they continue to jeopardize patient’s health.

Key publications of the Antiviral Pharmacology group.